AMBS - Amarantus BioScience Holdings, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0142
0.0000 (0.00%)
As of 12:57PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0142
Open0.0141
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0141 - 0.0145
52 Week Range0.0100 - 0.0765
Volume200,179
Avg. Volume434,869
Market Cap3.222M
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.0310
Earnings DateAug 18, 2016 - Aug 19, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
  • GlobeNewswire

    Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics

    New York, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that subsidiary MANF Therapeutics has been issued a Chinese patent covering the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) and/or cerebral dopamine neurotrophic factor (CDNF) for the treatment of retinal disorders. MANF Therapeutics is focused on the development of MANF as an intravitreal injection for the treatment of glaucoma, macular degeneration, retinitis pigmentosa and Wolfram Syndrome.

  • GlobeNewswire

    Amarantus Provides Recapitalization Update to Shareholders

    Pending license with Emerald provides opportunity to realize therapeutic portfolio valueJV w/Todos announces full enrollment for LymPro Alzheimer’s blood test clinical.

  • GlobeNewswire

    Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET

    Topline results are expected before the end of the first quarter of 2020. Breakthrough completed a 20-subject clinical study (LymPro PET 1) in 2018 evaluating the correlation between LymPro scores and the diagnosis of Alzheimer’s disease, as confirmed with amyloid PET neuroimaging and other Alzheimer’s disease biomarkers.

  • PR Newswire

    Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings

    Portfolio includes treatments for Alzheimer's disease, ADHD, Parkinson's disease, vision loss and severe burns Amarantus to receive Emerald Organics Preferred Stock for the exclusive worldwide license ...

  • GlobeNewswire

    Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products

    NEW YORK, NY, Oct. 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced it has entered into a binding term sheet to license its therapeutic assets to Emerald Organic Growth, Inc. (EMOR) (“Emerald” or EMOR), a fully-integrated, CBD-based health sciences company launching branded products via its nationwide distribution channels. Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022, and up to double digit royalties (in addition to passthrough royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to eltoprazine, engineered skin substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard.

  • GlobeNewswire

    Todos Medical to Present at Dawson James Small Cap Growth Conference

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that Company management will present at the Dawson James Small Cap Growth Conference on Tuesday, October 29, 2019 beginning at 3:15 P.M. Eastern time. Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis.

  • GlobeNewswire

    Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Orot+, the operational division of Orot-Luces (http://orot-luces.com), that executed a distribution agreement with Todos for the commercial distribution of Todos’ TM-B1and TM-B2 blood screening tests for breast cancer, today announced the enrollment of the first patient in the pre-commercial launch study of TM-B1 and TM-B2 in Europe. The pre-commercial launch study is expected to last approximately 6 months.

  • GlobeNewswire

    Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into a binding term sheet with HWH World Pte Ltd. (“HWH World”), a wholly-owned subsidiary of Singapore eDevelopment (40V.SI) for the grant of exclusive marketing rights for Todos Medical’s TM-B1 and TM-B2 tests to HWH World’s network of members in Singapore, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, South Korea, Hong Kong, China, the United States and Canada. HWH World is a marketing firm that focuses on health and wellness.

  • GlobeNewswire

    Todos Medical Enters into MOU to Expand Existing Early Detection Breast Cancer Blood Test Distribution Partnership with Orot+ into Japan

    Under the terms of the MOU, Orot+ has agreed to spend a minimum of $2.5M towards clinical development, regulatory approval and commercial launch of the tests by way of a soon to be formed Japanese Distribution Company which will be granted the exclusive rights to sell and distribute TM-B1 and TM-B2 in Japan. The execution of this MOU expands the relationship between Todos and Orot+, as the companies signed a definitive exclusive distribution agreement for both of TM-B1 and TM-B2 in Romania and Austria in April 2019.

  • GlobeNewswire

    Todos Medical Appoints Dr. Jorge Leon as Medical Advisor

    Dr. Leon previously played a key role in establishing and leading Quest Diagnostics’ Molecular Diagnostics laboratories. REHOVOT, Israel, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced the appointment of Jorge Leon, PhD, as a medical advisor to assist the Company in clinical development, regulatory strategy and fund raising.

  • GlobeNewswire

    Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET Interim Analysis

    REHOVOT, Israel, July 15, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostic company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease (AD), today announced positive results from a pre-specified interim analysis of 20 subjects from an ongoing 40-subject outpatient study evaluating the relationship between LymPro Test™ (LymPro) scores with amyloid PET imaging scores. The study is being conducted under the direction of Dr. Thomas Arendt at the University of Leipzig in Germany, with mild cognitive impairment (MCI) and dementia patients evaluated in the clinic of the Neurobiological Research group in the Department of Psychiatry and Psychotherapy. Todos Medical expects Leipzig to complete patient enrollment in the second half of 2019, and to disclose full results in a future scientific conference.

  • GlobeNewswire

    Todos Medical Announces Launch of Public Offering

    REHOVOT, Israel, July 11, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has launched a roadshow for a public offering of up to $7,000,000 of units.  Each unit issued in the offering will consist of one share of common stock and one warrant to purchase one share of common stock.  The common stock and warrants will be immediately separable from the units and will be issued separately.

  • GlobeNewswire

    Todos Medical to Sponsor the Investacure ‘Cure Coin Awards Reception’ for Alzheimer’s and CTE Research at AAIC 2019 in Los Angeles

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it will be sponsoring the Investacure ‘Cure Coin Awards Reception’ on Monday, July 15, 2019, at 7 p.m. at The Association, 110 East 6th Street, in downtown Los Angeles, CA. The reception is being hosted to honor researchers in Alzheimer’s and CTE who are working to turn scientific discoveries into clinical interventions that could alter the course of those two devastating neurodegenerative diseases. Todos Medical intends to release preliminary data regarding the LymPro Test’s utility for the detection of Alzheimer’s, based upon studies conducted at Leipzig University on the comparability of LymPro and amyloid PET imaging.

  • GlobeNewswire

    Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation

    NEW YORK, NY, June 25, 2019 -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding.

  • GlobeNewswire

    Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association

    NEW YORK, NY, June 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that positive results from in vitro and animal studies on MANF in the treatment of Wolfram Syndrome were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.

  • GlobeNewswire

    Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that CEO Herman Weiss, MD, MBA, FACOG, provided a corporate update and roadmap at  LD Micro International Annual Invitational in Los Angelos, California. From our flagship TBIA platform, our TM-B2 test is a blood test for breast cancer initially focused on replacing the current battery of tests performed on patients with dense breasts who have inconclusive mammogram results, a significant unmet medical need.

  • GlobeNewswire

    Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics

    New York, NY, June 13, 2019 -- via NEWEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding.

  • GlobeNewswire

    Amarantus to Present at 9th Annual LD Micro Invitational Conference

    New York, NY, June 04, 2019 -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding.

  • GlobeNewswire

    Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts

    Todos Medical Ltd. (TOMDF) (http://www.Todosmedical.com) today announced positive results from a clinical trial completed at CGH Hospital in Singapore. The study was focused primarily on subjects of Asian descent, a population in which women have the highest rate of dense breast tissue. The current standard of care is estimated to range from 50% accuracy in women with dense breasts and  an accuracy rate of 75% in the standard population.

  • GlobeNewswire

    Amarantus Releases Letter to Shareholders

    First, thank you for your continued support of the Company. With new data on our Alzheimer’s diagnostic blood test ‘LymPro’ in hand from Dr. Thomas Arendt’s lab at Leipzig University, our Joint Venture Partner Todos Medical, Ltd. (TOMDF) has exercised their exclusive option to acquire the remaining 80.01% of Amarantus’ subsidiary Breakthrough Diagnostics, Inc. Upon closing of the transaction, Amarantus will be a major shareholder in Todos, an exciting immune-based cancer diagnostics company based in Israel, headed by Herman Weiss, MD, former Global Medical Director of Women’s Health and Bone Health at Teva Pharmaceutical Industries, Ltd. With technology out of Ben-Gurion University, Todos is harnessing a unique understanding of the immune system to develop biomarker-based products to address key unmet needs in cancer.

  • GlobeNewswire

    Amarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Emerging Legal Hemp Industry

    New York, NY, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that it has engaged Evolution Venture Partners (www.evovp.com), a crossover-focused biopharmaceutical advisory and investment firm that is expanding its business into the legal cannabis sector, to assist the Company in evaluating potential business opportunities and strategic alternatives in the emerging legal hemp industry. The engagement is for a period of six months, during which time the Company will continue to execute on its biopharmaceutical holding company financing and spinoff model while it evaluates launching or acquiring hemp-based operations.

  • GlobeNewswire

    Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has received and analyzed data from the University of Leipzig on the lymphocyte proliferation test (‘LymPro”), which demonstrated a strong correlation between LymPro and amyloid PET. Upon review of the LymPro data, Todos Medical exercised its exclusive option to acquire the remaining 80.01% of its joint venture Breakthrough Diagnostics from Amarantus Bioscience Holdings, Inc. (AMBS).

  • GlobeNewswire

    Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has received approval from the Israeli Ministry of Health (AMAR) to market and sell its breast cancer tests TM-B1 and TM-B2. “We are happy to achieve this important milestone approval from the Ministry of Health of the State of Israel. This approval, along with our recent signing of a distribution agreement for our cancer screens with Care GB in Israel, enables us to move forward at full strength to commercialize our products,” said Dr. Herman Weiss, CEO of Todos Medical.

  • GlobeNewswire

    Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel

    Todos Medical Ltd. (TOMDF) a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders such as Alzheimer's disease, today announced the signing of a Distribution Agreement with Care G.B. Plus, Ltd. for exclusive distribution rights of Todos Medical Ltd.’s innovative and cost-effective TM-B2 blood tests for breast cancer screening in the State of Israel. “We recently have initiated commercialization of our breast cancer screen (TM-B1) in two European markets.

  • GlobeNewswire

    Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that Todos Medical’s Annual Shareholder Meeting was held on Monday, April 29, 2019. “This has been an exciting year for Todos Medical as we have moved forward on many key initiatives.